Munich – Biotech company Cherry Biolabs, a spin-off from Würzburg University Hospital and an exclusive licensee of Julius-Maximilians-University in Würzburg, has signed an exclusive sub-licence agreement with MorphoSys AG for the application of Hemibody technology. This gives MorphoSys the right to apply Cherry Biolabs’ multispecific technology to six exclusive target molecules. The technology will be used to develop new therapies for cancer patients with unmet medical needs and to apply these therapies in practice. Financial details of the agreement were not disclosed.
A CMS team headed by lead partner Stefan Lüft advised Cherry Biolabs on all legal aspects of the licence agreement. In addition to negotiation of the patent licensing agreement with MorphoSys, the advice also included close coordination with the University of Würzburg. Cherry Biolabs was represented in the negotiations by EMBL Ventures, a longstanding client of CMS Germany.
Cherry Biolabs holds the exclusive licence for the Hemibody platform technology, which was granted by the University of Würzburg. The firm intends to develop an internal drug pipeline and out-license the technology.
MorphoSys is a biopharmaceutical company with its own sales structures which is dedicated to the discovery, development and commercialisation of innovative therapies for patients suffering from serious diseases. Its focus is on cancer and autoimmune diseases.
Stefan Lüft, Lead Partner
Annika Lindemann, Senior Associate, both Intellectual Property
Jörg Schrade, Partner, Tax